Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Eli Lilly's triple agonist retatrutide beat Ozempic in a direct head-to-head phase 3 trial for type 2 diabetes. Both the 9 mg and 12 mg doses of retatrutide cut HbA1c by 2.2 percentage points vs. 1.8 with Ozempic, and delivered more than double the weight loss — up to 20.9% vs. 9.4%. The drug isn't approved yet, but Lilly says it could shift the treatment landscape for diabetes and obesity.
Eli Lilly's investigational triple receptor agonist retatrutide has outperformed Ozempic (semaglutide 2 mg) in the first phase 3 head-to-head trial comparing two incretin-based medicines. In the TRANSCEND-T2D-2 trial, 1,298 adults with type 2 diabetes who couldn't achieve glycemic control on metformin (with or without an SGLT2 inhibitor) were randomized to retatrutide 9 mg, 12 mg, or Ozempic 2 mg for 80 weeks.
Both retatrutide doses delivered a 2.2 percentage point drop in HbA1c vs. 1.8 points with Ozempic — and the weight loss gap was even more striking, with retatrutide 12 mg achieving 20.9% body weight reduction compared to just 9.4% with Ozempic. Retatrutide also showed greater improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure. The most common side effects were GI-related (nausea, diarrhea, constipation), and discontinuation rates were slightly higher with retatrutide (4.8–7.9%) vs. Ozempic (2.7%).
By the Numbers:
Why it matters: This is the first phase 3 trial to pit retatrutide directly against an approved incretin therapy, and the results are striking. If approved, retatrutide could redefine the standard of care for type 2 diabetes management — particularly for patients who need both meaningful glycemic control and substantial weight loss.
